JP5000050B2 - 抗腫瘍剤及びその製造方法 - Google Patents

抗腫瘍剤及びその製造方法 Download PDF

Info

Publication number
JP5000050B2
JP5000050B2 JP2001264918A JP2001264918A JP5000050B2 JP 5000050 B2 JP5000050 B2 JP 5000050B2 JP 2001264918 A JP2001264918 A JP 2001264918A JP 2001264918 A JP2001264918 A JP 2001264918A JP 5000050 B2 JP5000050 B2 JP 5000050B2
Authority
JP
Japan
Prior art keywords
znpp
peg
water
porphyrin
heme oxygenase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2001264918A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003073273A5 (enExample
JP2003073273A (ja
Inventor
浩 前田
智裕 沢
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to JP2001264918A priority Critical patent/JP5000050B2/ja
Application filed by Individual filed Critical Individual
Priority to PCT/JP2002/008707 priority patent/WO2003018007A1/ja
Priority to CA2458744A priority patent/CA2458744C/en
Priority to US10/484,726 priority patent/US7026488B2/en
Priority to DK02758880.5T priority patent/DK1421938T3/da
Priority to EP02758880A priority patent/EP1421938B1/en
Priority to ES02758880T priority patent/ES2339430T3/es
Priority to AT02758880T priority patent/ATE456951T1/de
Priority to CNB028171373A priority patent/CN100406010C/zh
Priority to DE60235279T priority patent/DE60235279D1/de
Priority to KR1020047001975A priority patent/KR100876343B1/ko
Publication of JP2003073273A publication Critical patent/JP2003073273A/ja
Publication of JP2003073273A5 publication Critical patent/JP2003073273A5/ja
Application granted granted Critical
Publication of JP5000050B2 publication Critical patent/JP5000050B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2001264918A 2001-08-31 2001-08-31 抗腫瘍剤及びその製造方法 Expired - Fee Related JP5000050B2 (ja)

Priority Applications (11)

Application Number Priority Date Filing Date Title
JP2001264918A JP5000050B2 (ja) 2001-08-31 2001-08-31 抗腫瘍剤及びその製造方法
CNB028171373A CN100406010C (zh) 2001-08-31 2002-08-29 抗癌剂及其制备方法
US10/484,726 US7026488B2 (en) 2001-08-31 2002-08-29 Antitumor agents and process for producing the same
DK02758880.5T DK1421938T3 (da) 2001-08-31 2002-08-29 Antitumormidler og fremgangsmåde til at producere samme
EP02758880A EP1421938B1 (en) 2001-08-31 2002-08-29 Antitumor agents and process for producing the same
ES02758880T ES2339430T3 (es) 2001-08-31 2002-08-29 Agentes antitumorales y procedimiento de produccion de los mismos.
PCT/JP2002/008707 WO2003018007A1 (en) 2001-08-31 2002-08-29 Antitumor agents and process for producing the same
CA2458744A CA2458744C (en) 2001-08-31 2002-08-29 Anticancer agents and preparation method of the same
DE60235279T DE60235279D1 (de) 2001-08-31 2002-08-29 Antitumorale mittel und verfahren zu ihrer herstellung
KR1020047001975A KR100876343B1 (ko) 2001-08-31 2002-08-29 항종양제 및 그 제조 방법
AT02758880T ATE456951T1 (de) 2001-08-31 2002-08-29 Antitumorale mittel und verfahren zu ihrer herstellung

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2001264918A JP5000050B2 (ja) 2001-08-31 2001-08-31 抗腫瘍剤及びその製造方法

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2011278412A Division JP2012087141A (ja) 2011-12-20 2011-12-20 抗腫瘍剤及びその製造方法

Publications (3)

Publication Number Publication Date
JP2003073273A JP2003073273A (ja) 2003-03-12
JP2003073273A5 JP2003073273A5 (enExample) 2008-01-31
JP5000050B2 true JP5000050B2 (ja) 2012-08-15

Family

ID=19091449

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001264918A Expired - Fee Related JP5000050B2 (ja) 2001-08-31 2001-08-31 抗腫瘍剤及びその製造方法

Country Status (11)

Country Link
US (1) US7026488B2 (enExample)
EP (1) EP1421938B1 (enExample)
JP (1) JP5000050B2 (enExample)
KR (1) KR100876343B1 (enExample)
CN (1) CN100406010C (enExample)
AT (1) ATE456951T1 (enExample)
CA (1) CA2458744C (enExample)
DE (1) DE60235279D1 (enExample)
DK (1) DK1421938T3 (enExample)
ES (1) ES2339430T3 (enExample)
WO (1) WO2003018007A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004196770A (ja) * 2002-10-24 2004-07-15 Effector Cell Institute Inc 樹状細胞前駆体の血中レベル上昇剤
GB2397067B (en) 2002-12-23 2005-05-11 Destiny Pharma Ltd Porphin & azaporphin derivatives with at least one cationic-nitrogen-containing meso-substituent for use in photodynamic therapy & in vitro sterilisation
GB2408265A (en) * 2003-11-21 2005-05-25 Univ Sheffield Water-soluble hyperbranched polymer porphyrins
GB2415372A (en) 2004-06-23 2005-12-28 Destiny Pharma Ltd Non photodynamical or sonodynamical antimicrobial use of porphyrins and azaporphyrins containing at least one cationic-nitrogen-containing substituent
EP1873204B1 (en) * 2005-04-18 2011-09-21 Hiroshi Maeda Polymeric pharmaceutical agent for treatment of cancer and process for production of the same
WO2008014266A2 (en) * 2006-07-24 2008-01-31 University Of Maryland, Baltimore Heme oxygenase inhibitors and methods of therapeutic use
WO2009015274A2 (en) * 2007-07-24 2009-01-29 University Of Florida Research Foundation, Inc. Polyethylene based bioactive agents
JP2010024170A (ja) * 2008-07-17 2010-02-04 Hiroshi Maeda 抗悪性腫瘍剤の腫瘍組織への局所送達増強剤
CN102000070B (zh) * 2009-07-08 2012-05-23 山东弘立医学动物实验研究有限公司 用于治疗肿瘤的锰卟啉-氯尼达明联合用药物
KR101164138B1 (ko) 2009-12-24 2012-07-11 재단법인대구경북과학기술원 광역학 치료용 수용성 나노구조체
CN101948566B (zh) * 2010-06-23 2012-09-19 中国科学院化学研究所 一种用于抗真菌、抗癌及细胞成像的多功能聚合物及其制备方法
HUE032791T2 (en) * 2011-09-05 2017-11-28 Hiroshi Maeda Polymer-type fluorescent molecule probe
CN104069492B (zh) * 2014-01-24 2019-05-28 中国科学院福建物质结构研究所 靶向表达尿激酶受体的肿瘤的光敏剂及其制备方法和用途
CN108610346B (zh) * 2018-04-02 2020-06-02 杭州至重医药科技有限公司 一种光敏酞菁固体材料及其制备方法与应用
CN114262442B (zh) * 2021-12-24 2023-05-02 厦门金达威生物科技有限公司 一种两亲聚合物和脂溶性营养素纳米颗粒及其制备方法
CN119456038A (zh) * 2025-01-14 2025-02-18 浙江工业大学 一种金属卟啉基柔性共轭有机聚合物-卤氧铋复合材料及制备方法和光催化co2还原应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2645079A1 (de) * 1976-10-06 1978-04-13 Bayer Ernst Polymere sauerstofftraeger und verfahren zu ihrer herstellung
JPS584061B2 (ja) * 1979-04-27 1983-01-24 森六株式会社 ブロック共重合体金属錯体
EP0529002B1 (en) 1990-05-15 2001-10-04 Hyperion, Inc. Fluorescent porphyrin, and fluorescent phthalocyanine - polyethylene glycol, polyol, and saccharide derivatives as fluorescent probes
US5622685A (en) * 1990-05-30 1997-04-22 Deutches Krebsforchunszentrum Stiftung Des Offentlichen Rechts Polyether-substituted porphyrin anti-tumor agents
EP0502723B1 (en) 1991-03-05 1996-10-09 Hitachi Chemical Co., Ltd. Water-soluble tetraazaporphins and fluorochrome for labeling
US6362175B1 (en) * 1991-09-20 2002-03-26 The Trustees Of The University Of Pennsylvania Porphyrin compounds for imaging tissue oxygen
DE69129150T2 (de) * 1991-10-14 1998-10-08 The Procter & Gamble Co., Cincinnati, Ohio Waschmittelzusammensetzungen mit Zusätzen zur Verhinderung der Farbstoffübertragung
DE4232925A1 (de) 1992-09-28 1994-03-31 Diagnostikforschung Inst 3-,8-substituierte Deuteroporphyrinderivate, diese enthaltende pharmazeutische Mittel und Verfahren zu ihrer Herstellung
GB9408746D0 (en) * 1994-05-03 1994-06-22 Scotia Holdings Plc Tumour locallising photosensitising compounds
US5591422A (en) * 1995-06-02 1997-01-07 Pharmacyclics, Inc. Texaphyrin complexes having improved functionalization
US20020155999A1 (en) * 1998-04-30 2002-10-24 Han In Suk Method of using a porphyrin-like molecule conjugated with an anti-cancer drug for the treatment of cancer
GB0001455D0 (en) * 2000-01-21 2000-03-15 Scotia Holdings Plc Porphyrins and related compounds

Also Published As

Publication number Publication date
EP1421938A1 (en) 2004-05-26
CN100406010C (zh) 2008-07-30
KR100876343B1 (ko) 2008-12-29
CA2458744C (en) 2010-09-14
CA2458744A1 (en) 2003-03-06
JP2003073273A (ja) 2003-03-12
DE60235279D1 (de) 2010-03-25
EP1421938B1 (en) 2010-02-03
EP1421938A4 (en) 2005-11-23
ES2339430T3 (es) 2010-05-20
US7026488B2 (en) 2006-04-11
CN1549712A (zh) 2004-11-24
WO2003018007A1 (en) 2003-03-06
KR20040030951A (ko) 2004-04-09
US20040234495A1 (en) 2004-11-25
DK1421938T3 (da) 2010-05-17
ATE456951T1 (de) 2010-02-15

Similar Documents

Publication Publication Date Title
KR100876343B1 (ko) 항종양제 및 그 제조 방법
JP5944836B2 (ja) 高分子薬物送達結合体ならびにその製造および使用方法
US5773522A (en) Polymer-bound camptothecin derivatives
JP7824983B2 (ja) カンプトテシン類医薬品及びその抗体複合体
CN112047952A (zh) 一种喜树碱-光敏剂前药及其制备方法和应用
WO2015081821A1 (zh) 聚乙二醇-多爪寡肽键合的雷帕霉素衍生物
RU2569847C2 (ru) Фармацевтическая композиция, содержащая блок-сополимер, включающий соединение бороновой кислоты
US20030166513A1 (en) Dds compound and process for the preparation thereof
AU2003282354B2 (en) Water-soluble anionic bacteriochlorophyll derivatives and their uses
CN111718395B (zh) 一种前药激活化合物、前药体系及其制备方法和应用
JP2003073273A5 (enExample)
JP2012087141A (ja) 抗腫瘍剤及びその製造方法
EP4190361A1 (en) Polyethylene glycol conjugate drug, and preparation method therfor and use thereof
CN112316139B (zh) 一种吲哚菁绿纳米药物及其制备方法
WO2007075119A1 (en) Pharmaceutical composition for photodynamic therapy and a method for treating oncological diseases by using said composition
CN113710323B (zh) 偶联物及癌治疗剂
US11596643B2 (en) Pectin-adriamycin conjugate as well as preparation method and use thereof
JPH07173080A (ja) メトトレキセート誘導体とピラン共重合体の高分子結合体及びその製造方法
KR20220109877A (ko) 환원반응성 일산화질소 공여 화합물 및 전달체 시스템
US20170128579A1 (en) Method of synthesizing polysaccharide conjugates and method for cancer therapy

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20071212

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20071212

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20100610

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100628

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20100629

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110517

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110719

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20110920

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20111220

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20120221

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20120417

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20120516

R150 Certificate of patent or registration of utility model

Ref document number: 5000050

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20150525

Year of fee payment: 3

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees